氧化应激对潜在口腔恶性疾病作用的研究进展

doi:10.13701/j.cnki.kqyxyj.2021.02.004

摘要/Abstract

摘要： 潜在口腔恶性疾病(oral potentially malignant disorders , OPMD)是一类具有癌变潜能的口腔疾病,其发病机制尚未明确。研究表明,口腔扁平苔藓(oral lichen planus,OLP)、口腔白斑、口腔黏膜下纤维性变(oral submucous fibrosis,OSF)患者体内存在氧化应激 (oxidative stress, OS)现象,伴随脂质过氧化、DNA损伤以及抗氧化系统失衡。其中,活性氧 (reactive oxygen species, ROS)及其引起的氧化损伤与疾病的发生发展密切相关。通过它们与氧化应激的研究进展,可进一步阐明发病机制,并为疾病的预防和抗氧化治疗提供新的思路。

关键词: 氧化应激, 潜在口腔恶性疾病, 活性氧族

Abstract: Oral potentially malignant disorders (OPMD) are clinical presentations that carry a risk of cancer development in the oral cavity, and its pathogenesis is still unclear. Studies have shown that oxidative stress (OS) is associated with the lipid peroxidation and DNA damage and the imbalance of antioxidant system in patients with oral lichen planus, oral leukoplakia, and oral submucosal fibrosis. The oxidative damage caused by reactive oxygen species (ROS) is closely related to the occurrence and development of them. Through the research of OS and these diseases, the pathogenesis of OS can be further clarified and new ideas for the prevention and antioxidant treatment of the disease can be provided.

Key words: oxidative stress, oral potentially malignant disorders, reactive oxygen species

沙桐, 张伟. 氧化应激对潜在口腔恶性疾病作用的研究进展[J]. 口腔医学研究, 2021, 37(2): 109-112.

SHA Tong, ZHANG Wei. Effects of Oxidative Stress on Oral Potentially Malignant Disorders[J]. Journal of Oral Science Research, 2021, 37(2): 109-112.

参考文献

[1] Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis [J]. Redox Biol, 2019, 20:247-260.
[2] Réus GZ, Carlessi AS, Silva RH, et al. Relationship of oxidative stress as a link between diabetes mellitus and major depressive disorder [J]. Oxid Med Cell Longev, 2019, 2019:8637970.
[3] Jia L, Xiong Y, Zhang W, et al. Metformin promotes osteogenic differentiation and protects against oxidative stress-induced damage in periodontal ligament stem cells via activation of the Akt/Nrf2 signaling pathway [J]. Exp Cell Res, 2020, 386(2):111717.
[4] Moloney JN, Cotter TG. ROS signalling in the biology of cancer [J]. Semin Cell Dev Biol, 2018, 80:50-64.
[5] El-Naggar AK, Chan JKC, Grandis JR, et al. WHO classification of head and neck tumours [M]. 4th edition, Lyon: IARC Press, 2017:112.
[6] Snezhkina AV, Kudryavtseva AV, Kardymon OL, et al. ROS generation and antioxidant defense systems in normal and malignant cells[J]. Oxid Med Cell Longev, 2019, 2019:6175804.
[7] Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem, 2017, 524:13-30.
[8] Cruz AF, Vitório JG, Duarte-Andrade FF, et al. Reticular and erosive oral lichen planus have a distinct metabolomic profile: A preliminary study using gas chromatography-mass spectrometry [J]. Oral Pathol Med, 2019, 48(5):400-405.
[9] Liu T, Zhang H, Yang X, et al. Study on expression of p16 and human papillomavirus 16 and 18 (E6) in OLP and its malignant transformation[J]. Pathol Res Pract, 2018, 214(2):296-302.
[10] Yang XY, Li XZ, Zhang SN. Metabolomics analysis of oral mucosa reveals profile perturbation in reticular oral lichen planus [J]. Clin Chim Acta, 2018, 487:28-32.
[11] Rekha VR, Sunil S, Rathy R. Evaluation of oxidative stress markers in oral lichen planus [J]. Oral Maxillofac Pathol, 2017, 21(3):387-393.
[12] Darczuk D, Krzysciak W, Vyhouskaya P, et al. Salivary oxidative status in patients with oral lichen planus [J]. Physiol Pharmacol, 2016, 67(6):885-894.
[13] Bakhtiari S, Toosi P, Samadi S, et al. Assessment of uric acid level in the saliva of patients with oral lichen planus [J]. Med Princ Pract, 2017, 26(1):57-60.
[14] Tvarijonaviciute A, Aznar-Cayuela C, Rubio CP, et al. Salivary antioxidant status in patients with oral lichen planus:correlation with clinical signs and evolution during treatment with chamaemelum nobile [J]. Biomed Res Int, 2018, 2018:5187549.
[15] Mansourian A, Shanbehzadeh N, Kia SJ, et al. Increased salivary aldehyde dehydrogenase 1 in non-reticular oral lichen planus [J]. An Bras Dermatol, 2017, 92(2):168-171.
[16] Chen X, Hu Q, Wu T, et al. Proteomics-based investigation of multiple stages of OSCC development indicates that the inhibition of Trx-1 delays oral malignant transformation [J]. Int J Oncol, 2018, 52(3):733-742.
[17] Lopez Jornet P, Aznar-Cayuela C. Efficacy of topical chamomile management vs. placebo in patients with oral lichen planus: a randomized double-blind study [J]. Eur Acad Dermatol Venereol, 2016, 30(10):1783-1786.
[18] White CM, Chamberlin K, Eisenberg E. Curcumin, a turmeric extract, for oral lichen planus: A systematic review [J]. Oral Dis, 2019, 25(3):720-725.
[19] Yang JY, Zhang J, Zhou G. Black pepper and its bioactive constituent piperine: promising therapeutic strategies for oral lichen planus [J]. Inflammopharmacology, 2019, 27(1):5-13.
[20] Babiuch K, Bednarczyk A, Gawlik K, et al. Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study [J]. Acta Odontol Scand, 2019, 77(6):408-418.
[21] Srivastava KC, Shrivastava D. Analysis of plasma lipid peroxidation and antioxidant enzymes status in patients of oral leukoplakia: A case control study [J]. Int Soc Prev Community Dent, 2016, 6(Suppl 3):S213-S218.
[22] Senghore T, Li YF, Sung FC, et al. Biomarkers of oxidative stress associated with the risk of potentially malignant oral disorders [J]. Anticancer Res, 2018, 38(9):5211-5216.
[23] Choudhari SK, Chaudhary M, Gadbail AR, et al. Oxidative and antioxidative mechanisms in oral cancer and precancer: a review [J]. Oral Oncol, 2014, 50(1):10-8.
[24] Yoshida T, Terabe T, Nagai H, et al. Association between p62 expression and clinicopathological characteristics in oral leukoplakia [J]. Clin Exp Dent Res, 2019, 5(4):389-397.
[25] Shah PH, Venkatesh R, More CB. Determination of role of ceruloplasmin in oral potentially malignant disorders and oral malignancy-A cross-sectional study [J]. Oral Dis, 2017, 23(8):1066-1071.
[26] Guttenplan JB, Chen KM, Sun YW, et al. Effects of black raspberry extract and protocatechuic acid on carcinogen-DNA adducts and mutagenesis, and oxidative stress in rat and human oral cells [J]. Cancer Prev Res (Phila), 2016, 9(8):704-712.
[27] Avinash Tejasvi ML, Bangi BB, Geetha P, et al. Estimation of serum superoxide dismutase and serum malondialdehyde in oral submucous fibrosis: a clinical and biochemical study [J]. Cancer Res Ther, 2014, 10(3):722-725.
[28] Bose KS, Vyas P, Singh M. Plasma non-enzymatic antioxidants-vitamin C, E,beta-carotenes, reduced glutathione levels and total antioxidant activity in oral sub mucous fibrosis [J]. Eur Rev Med Pharmacol Sci, 2012, 16(4):530-532.
[29] Pitiyage GN, Slijepcevic P, Gabrani A, et al. Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases [J]. J Pathol, 2011, 223(5):604-617.
[30] Rehman A, Ali S, Lone MA, et al. Areca nut alkaloids induce irreparable DNA damage and senescence in fibroblasts and may create a favourable environment for tumour progression [J]. J Oral Pathol Med, 2016, 45(5):365-372.
[31] Chang MC, Chen YJ, Chang HH, et al. Areca nut components affect COX-2, cyclin B1/cdc25C and keratin expression, PGE2 production in keratinocyte is related to reactive oxygen species, CYP1A1,Src, EGFR and Ras signaling [J]. PLoS One, 2014, 9(7):e101959.
[32] Arakeri G, Boraks G, Aljabab AS, et al. Breath Alkane as an index of severity for oral submucous fibrosis: A new perspective? [J]. Med Hypotheses, 2017, 98:18-20.
[33] Kumar MA, Radhika B, Gollamudi N, et al. Hyperbaric oxygen therapy-a novel treatment modality in oral submucous fibrosis: a review [J]. Clin Diagn Res, 2015, 9(5):ZE01-ZE04.
[34] Salehi B, Lopez-Jornet P, Pons-Fuster López E, et al. Plant-derived bioactives in oral mucosal lesions: a key emphasis to curcumin, lycopene, chamomile, aloe vera, green tea and coffee properties[J]. Biomolecules, 2019, 9(3):106.